(Alliance News) - The FTSE 100 closed lower on Wednesday, held back by falls in drugs firms GSK and AstraZeneca, while oil surged amid reports that the US is eyeing a longer blockade of the Strait of Hormuz. Read More
(Alliance News) - Cambridge, England-based pharmaceutical firm AstraZeneca PLC will pump GBP300 million into UK drugs development in a "major vote of confidence" in the country, the prime minister has said. Read More
(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Wednesday. Read More
(Alliance News) - Stock prices in London opened lower on Wednesday, as renewed uncertainty in energy markets and a heavy slate of corporate updates weighed on sentiment ahead of the Fed's rate call. Read More
(Alliance News) - AstraZeneca PLC on Wednesday reported better-than-expected first-quarter revenue and profit, and flagged the potential for its drugs pipeline amid numerous positive trial findings and regulatory approvals. Read More
(Alliance News) - AstraZeneca, Lloyds Banking Group and GSK report higher earnings in the first quarter. Read More
AstraZeneca PLC - Cambridge, England-based pharmaceutical maker - Breztri Aerosphere is approved by the US Food & Drug Administration as a maintenance treatment for asthma in patients 12 years and older. Breztri is a fixed-dose triple-combination therapy. It already was approved by the FDA in 2020 for the treatment of adults with chronic obstructive pulmonary disease. Astra says the new indication follows trials in which Breztri showed a "statistically significant and clinically meaningful improvement in lung function". Astra notes that Breztri is a maintenance therapy and isn't meant to replace a rescue inhaler to relieve sudden breathing problems. It says filings for Breztri in asthma are under review in the EU, Japan and China. Read More
(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Monday. Read More
(Alliance News) - AstraZeneca PLC on Monday said its self-administered lupus treatment has been approved in the US. Read More
(Alliance News) - GSK reports on a US court ruling in ongoing litigation, AstraZeneca announces US approval for a self-administered lupus treatment, while Harworth Group receives planning consent for a data centre development in Leeds. Read More
(Alliance News) - The FTSE 100 ended the week on the back foot as the crisis in the Middle East remained deadlocked. Read More
AstraZeneca PLC - Cambridge, England-based biopharmaceutical maker - Rene Haas will step down as a non-executive director on Thursday next week, the end of April, due to his increased executive duties. Haas is the chief executive officer of UK-based computer-chip designer Arm Holdings PLC and earlier this week was named to the additional role of CEO of SoftBank Group International. Japanese technology investor SoftBank Group Corp remains a major shareholder in Arm following its New York listing in 2023, retaining a 90% stake at the time. Read More
(Alliance News) - AstraZeneca PLC on Tuesday reported positive findings from trial results studying its kidney disease treatment, Ultomiris. Read More
(Alliance News) - AstraZeneca PLC on Monday reported positive phase three results for its monoclonal antibody, Tozorakimab, meeting its primary endpoint in the Miranda trial in patients with chronic obstructive pulmonary disease. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and on Thursday: Read More
(Alliance News) - AstraZeneca PLC on Thursday posted encouraging phase-three trial results for its liver cancer treatment combination. Read More
(Alliance News) - AstraZeneca PLC on Tuesday said phase-three testing of its replacement efzimfotase alfa enzyme on patients affected by hypophosphatasia yielded positive safety and efficacy results. Read More
(Alliance News) - Blue chips in London outperformed European and US peers on Friday, but closed marginally lower, as oil prices rose once more amid few signs of progress in ending the Iran war. Read More